Regeneron pharmaceuticals (regn) faces securities class action after losing $9 billion value following q3 2024 earnings report– hagens berman

Regn investors with losses encouraged to contact the firm before mar. 10th, 2025 deadline san francisco, ca / access newswire / february 25, 2025 / regeneron pharmaceuticals inc. (nasdaq:regn) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. td cowen recently lowered its price target for regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for eylea®, a key product.
REGN Ratings Summary
REGN Quant Ranking